Cidara Therapeutics
(NASDAQ) CDTX
Cidara Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$0.00
Net Income (TTM)
$184.74M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
CDTX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Cidara Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
38
CEO
Jeffrey L. Stein, PhD
Website
www.cidara.comHeadquarters
San Diego, CA 92121, US
CDTX Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-60%
Return on Capital
-46%
Return on Assets
-36%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$1.27M
Operating Income
$176.10M
EBITDA
$175.87M
Operating Cash Flow
$176.53M
Capital Expenditure
$129.00K
Free Cash Flow
$176.66M
Cash & ST Invst.
$189.82M
Total Debt
$3.58M
Cidara Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$45.00M
N/A
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
38
N/A
Net Income
$83.23M
-420.7%
EBITDA
$83.20M
-380.0%
Quarterly Fundamentals
Net Cash
$291.67M
+136.3%
Accounts Receivable
$1.86M
+9.5%
Inventory
$0.00
N/A
Long Term Debt
$424.00K
-82.0%
Short Term Debt
$1.56M
-1.3%
Return on Assets
-35.62%
N/A
Return on Invested Capital
-46.23%
N/A
Free Cash Flow
$40.62M
-10.4%
Operating Cash Flow
$40.62M
-10.7%